Morgan Stanley analyst Judah Frommer initiated coverage of Agomab with an Overweight rating and $28 price target. The firm says the company developing ontunisertib and AGMB-447 for fibrotic conditions. While the data are early for both programs, the stock's risk/reward is skewed to the upside heading into 2026 based, the analyst tells investors in a research note.
